A, Kloner RA. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 297: H1923-H1929, 2009. First published September 18, 2009 doi:10.1152/ajpheart.00173.2009We tested the effect of the antianginal agent ranolazine on ventricular arrhythmias in an ischemic model using two protocols. In protocol 1, anesthetized rats received either vehicle or ranolazine (10 mg/kg, iv bolus) and were subjected to 5 min of left coronary artery (LCA) occlusion and 5 min of reperfusion with electrocardiogram and blood pressure monitoring. In protocol 2, rats received either vehicle or three doses of ranolazine (iv bolus followed by infusion) and 20 min of LCA occlusion. With protocol 1, ventricular tachycardia (VT) occurred in 9/12 (75%) vehicle-treated rats and 1/11 (9%) ranolazinetreated rats during reperfusion (P ϭ 0.003). Sustained VT occurred in 5/12 (42%) vehicle-treated but 0/11 in ranolazine-treated rats (P ϭ 0.037). The median number of episodes of VT during reperfusion in vehicle and ranolazine groups was 5.5 and 0, respectively (P ϭ 0.0006); median duration of VT was 22.2 and 0 s in vehicle and ranolazine rats, respectively (P ϭ 0.0006). With protocol 2, mortality in the vehicle group was 42 vs. 17% (P ϭ 0.371), 10% (P ϭ 0.162) and 0% (P ϭ 0.0373) with ranolazine at plasma concentrations of 2, 4, and 8 M, respectively. Ranolazine significantly reduced the incidence of ventricular fibrillation [67% in controls vs. 42% (P ϭ 0.414), 30% (P ϭ 0.198) and 8% (P ϭ 0.0094) in ranolazine at 2, 4, and 8 M, respectively]. Median number (2.5 vs. 0; P ϭ 0.0431) of sustained VT episodes, incidence of sustained VT (83 vs. 33%, P ϭ 0.0361), and the duration of VT per animal (159 vs. 19 s; P ϭ 0.0410) were also significantly reduced by ranolazine at 8 M. Ranolazine markedly reduced ischemia-reperfusion induced ventricular arrhythmias. Ranolazine demonstrated promising anti-arrhythmic properties that warrant further investigation.
THERE ARE FEW SAFE AND EFFECTIVE anti-arrhythmic drugs for use in patients with ischemic heart disease. Class I anti-arrhythmic agents such as quinidine, flecanide, propafenone, and procainamide have the potential to be proarrhythmic in the setting of ischemic heart disease and should be used with caution (4) . The use of ␤-adrenergic receptor blockers and calcium channel blockers such as diltiazem and verapamil may be limited by side effects such as heart rate slowing (11) . Hence, there remains an unmet need for safe and effective anti-arrhythmic agents. Ranolazine has been approved in the United States and Europe for the treatment of chronic angina pectoris (i.e., myocardial ischemia) (2, 11) . Recent experimental studies have shown that ranolazine has certain cardioprotective properties in the setting of ischemia-reperfusion (8 -10) . It reduces experimental S-T segment elevation and myocardial infarct size and enhances function of stunned myocardium in the peri-infarct area (8) . However, there is a lack of data regarding the effect of ranolazine on ventricular arrhythmias in in vivo models of S-T segment elevation myocardial infarction (MI).
In the present study, we hypothesized that the late sodium current inhibitor ranolazine might protect ischemic and ischemic-reperfused tissues from ventricular arrhythmias in vivo. Therefore, two sets of experiments were performed in independent laboratories. One laboratory used a model of brief ischemia-reperfusion (5 min each) that reliably results in severe ventricular arrhythmias during the reperfusion phase, and previously had been shown to be useful for testing the effects of pre-and postconditioning (7, 12) . The second laboratory used longer (20 min) coronary artery occlusion to study only ischemia-induced ventricular arrhythmias (3) . At the time the studies were carried out, neither laboratory knew of the other's work. Hence, the models differ regarding technical details. Notwithstanding the differences between the two models, the results of both studies indicate that ranolazine reduces the incidence and duration of ventricular arrhythmias in the intact rat heart subjected to ischemia.
METHODS
All experimental procedures were approved by their respective Institutional Animal Care and Use Committees. Figure 1 shows a schematic of the two protocols used in the study.
Protocol 1: effect of ranolazine on reperfusion-induced arrhythmias. Sprague Dawley female rats weighing 223 to 333 g were anesthetized with pentobarbital sodium (55 mg/kg ip). The neck and chest were shaved, the trachea was intubated, and the rat was mechanically ventilated with a small animal respirator (model 683; Harvard Apparatus). The left jugular vein was cannulated for injection of Unisperse blue dye and KCl at the close of the protocol. The right carotid artery was cannulated for monitoring of systemic blood pressure and heart rate. Cardiac rhythm was monitored using standard electrocardiogram (ECG) limb lead II throughout the study. Body temperature was monitored via a rectal thermometer and maintained at 37°C with a water-filled heating pad.
A left thoracotomy was performed at the fourth intercostal space, and ribs were retracted to expose the heart. The pericardium was removed, and a 4-0 silk suture was passed under the proximal left coronary artery in the interventricular groove, just below the left atrial appendage. The suture was threaded through a plastic tube to create a snare. A 5-min coronary artery occlusion was induced by tightening the snare. After 5 min, the snare was released to allow coronary artery reperfusion. Rats were randomized to receive either vehicle (ϳ 0.05 N HCl in saline) or a single bolus of ranolazine (10 mg/kg iv bolus) in vehicle 16 min before coronary occlusion. At the end of the 5-min period of reperfusion, the coronary artery was reoccluded at the same site. Unisperse blue dye was injected intravenously, and the rat was then killed under deep anesthesia with an intravenous injection of KCl. The heart was excised, sliced transversely from apex to base into four to five slices, and photographed. Ischemic tissue was defined as tissue that did not stain blue, but remained pink, whereas nonischemic myocardium was stained blue. Computerized planimetry then was used to determine the ischemic area, expressed as a percentage of the left ventricle and corrected for the weight of the ventricular slices. The incidence and frequency of ventricular arrhythmias and ventricular premature beats (VPBs) during ischemia and reperfusion in the absence and presence of ranolazine were quantified.
Protocol 2: effect of ranolazine on ischemia-induced ventricular arrhythmias. Male Sprague Dawley rats weighing 290 -310 g were anesthetized with pentobarbital sodium (65 mg/kg ip). The trachea was intubated, and rats were artificially ventilated. The right external jugular vein and the left carotid artery were cannulated for intravenous injections and recording of blood pressure, respectively. Lead II of the ECG was recorded. Body temperature was monitored via a rectal thermometer and maintained at 36 -37°C using a water-filled heating pad. An occluder was placed loosely around the left coronary artery. After the occluder was placed, the chest was closed, and 15-30 min were allowed for postsurgical recovery and hemodynamic equilibration. Ranolazine or vehicle (1% ascorbic acid in saline) was given as an intravenous bolus followed by an infusion. The dose regimens for ranolazine were 2 mg/kg followed by 4.8 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 (low dose), 4 mg/kg followed by 7.2 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 (middle dose), and 10 mg/kg followed by 9.6 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 (high dose), targeted to achieve plasma concentrations of 2, 4, and 8 M. After 30 min of infusion with ranolazine, the left coronary artery was occluded by tightening the snare of the occluder, and arrhythmias were recorded for 20 min. At the end of 20 min of ischemia, the ischemic risk zone was visualized by perfusing the heart with Alcian blue in saline through the ascending aorta. The nonperfused area (pink) was then cut out and calculated as a percentage of total ventricular weight.
Plasma concentrations of ranolazine were determined in a separate group of animals using high-performance liquid chromatographytandem mass spectrometric assay following protein precipitation.
Data and statistical analysis. Any ventricular tachycardia (VT) was defined as three or more consecutive, abnormal ventricular beats. Sustained VT was any run of VT lasting 10 s or longer in duration. Mean arterial pressure (MAP) was calculated as 1/3 systolic ϩ 2/3 diastolic blood pressure.
Fisher's exact test was used to analyze categorical variables (presence or absence of various arrhythmias and mortality). Because the number of runs of VT and ventricular fibrillation (VF), the duration of those runs, and the number of VPBs were not normally distributed variables, the nonparametric Wilcoxon Exact test or Kruskal Wallis test was used to assess the significance of treatment effects, and the values are presented as median values. The area at risk as a percentage of the left ventricle is expressed as the mean Ϯ SE. Hemodynamics and ECG intervals are expressed as means Ϯ SE. The significance of differences in hemodynamics and ECG intervals between groups was assessed by repeated-measures ANOVA. A P value Ͻ0.05 was considered statistically significant.
RESULTS

Protocol 1: effect of ranolazine on ischemia-reperfusioninduced arrhythmias.
Reperfusion of the heart following a 5-min coronary occlusion resulted in arrhythmic activity in all control hearts tested and 45% of ranolazine hearts (Table 1 ). In ranolazine-treated hearts, the incidence, frequency, and duration of VT were strikingly reduced compared with control, during the 5 min of reperfusion (Table 1 and Fig. 2 ). Ranolazine treatment completely prevented episodes of sustained VT. Whereas 9/12 saline-treated rats developed VT, only one ranolazine-treated rat developed VT. The number of animals that developed VPBs was reduced by more than one-half with ranolazine treatment (P ϭ 0.005), and the total number of VPBs was markedly reduced by ranolazine (P Ͻ 0.0001). No rat in either group developed VF in this protocol.
During the 5-min period of ischemia that preceded reperfusion, the median episodes of VT were one in both control and ranolazine-treated groups (usually a short run within the 1st min of coronary occlusion) ( Table 2 ). The median number of VPBs was lower in the ranolazine than in the control group (P ϭ 0.005). Ranolazine significantly reduced both heart rate and blood pressure during ischemia and reperfusion (Fig. 3) . The ischemic risk zones as a percentage of left ventricle mass were similar between the control (31.8 Ϯ 1.6%) and ranolazine groups (35.0 Ϯ 2.5%, mean Ϯ SE; P ϭ 0.29).
Protocol 2: effect of ranolazine on ischemia-induced ventricular arrhythmias. Coronary artery occlusion for 20 min resulted in VPBs, VT and VF. Representative ECG and arterial pressure tracings from a vehicle-treated rat subjected to ischemia are shown in Fig. 4 . VF was associated with a significant decrease in MAP. Ranolazine significantly reduced the incidence, number of episodes and durations of Values are medians with % in parentheses. Median values for the no. of episodes and duration of VT are given in the bottom 4 rows; n, no. of rats. VT, ventricular tachycardia; VPB, ventricular premature beat. VF and sustained VT, and mortality due to VF (Table 3) in a dose-dependent manner. VF occurred in 67% of vehicletreated rats vs. 42% (P ϭ 0.414), 30% (P ϭ 0.198), and 8% (P ϭ 0.0094) of rats treated with low, middle, and high dose ranolazine, respectively. Sustained VT occurred in 67% (low dose), 50% (middle dose), and 33% (high dose) of ranolazine-treated rats compared with 83% in vehicletreated rats (P ϭ 0.640, P ϭ 0.172, and P ϭ 0.0361 for low, middle, and high dose, respectively). The median duration of VT was 19 s in rats treated with the high dose of ranolazine compared with 159 s in control rats (P ϭ 0.0431). Mortality rate was 42% in the vehicle group vs. 17% (P ϭ 0.371), 10% (P ϭ 0.162), and 0% (P ϭ 0.0373) in the ranolazine low, middle, and high dose groups, respectively (Table 3 ). The ischemic risk zones in control and ranolazine-treated rats were similar (vehicle ϭ 37 Ϯ 2%, n ϭ 12; low dose ϭ 35 Ϯ 1%, n ϭ 12; middle dose ϭ 37 Ϯ 1%, n ϭ 10; and high dose ϭ 39 Ϯ 1%, n ϭ 12).
There was a transient decrease in heart rate and MAP (Fig. 5 ) and transient increase in PR, QRS, and QT intervals (Fig. 6) were associated with the bolus injection of ranolazine and were significant only at higher doses. At the time of induction of ischemia, values of all parameters had returned to normal and were not different from those of vehicle-treated animals. No arrhythmic episodes were seen during the 30-min ranolazine infusion before the coronary artery occlusion.
Plasma levels of ranolazine were determined in a separate group of animals treated in an identical manner as to the study group. The three dose regimens resulted in initial plasma concentrations of 5, 13, and 23 M and sustained Values are medians with % in parentheses. Median values for the no. of episodes and duration of VT are given in the bottom 4 rows; n, no. of rats. Fig. 3 . Heart rate (beats/min) and mean arterial pressure (mmHg) in salinetreated and ranolazine-treated rats in protocol 1 at baseline, within 1 min postinjection of iv ranolazine (10 mg/kg), immediately before coronary occlusion, at the end of a 5-min occlusion, and after 5 min of reperfusion. Values are given as means Ϯ SE. *P Ͻ 0.0001 vs. control (saline), using repeatedmeasures ANOVA. plasma concentrations around 2, 6, and 10 M, respectively (Fig. 7) .
DISCUSSION
In the present study, two independent laboratories demonstrated the anti-arrhythmic effects of ranolazine in two different models: one of brief ischemia-reperfusion to assess reperfusion arrhythmias and another of prolonged ischemia without reperfusion. In both models, ranolazine demonstrated significant antiarrhythmic properties. Ranolazine markedly reduced the incidence, frequency, and duration of VT, including sustained VT in the ischemia-reperfusion model, and it also reduced VPBs. In the ischemia model, ranolazine reduced the incidence and duration of VF and decreased mortality in a dose-dependent manner. Ranolazine also reduced the frequency and duration of VT. To the best of our knowledge, these are the first reports of the antiarrhythmic effects of ranolazine to reduce ischemia and ischemia-reperfusion-induced ventricular arrhythmias in in vivo animal models that mimic the early phase of S-T segment elevation MI or Prinzmetal's angina.
Effect on hemodynamics. The initial intravenous bolus of ranolazine was associated with reductions in blood pressure and heart rate in both protocols used in this study. These changes were transient as MAP and heart rate returned to baseline by 30 min in the sustained ischemia protocol. The transient hemodynamic responses observed in our study are likely due to the very high plasma levels (23 M at the highest dose) achieved during the initial intravenous bolus administra- tion of ranolazine in anesthetized rats (Fig. 7) . These hemodynamic changes differ from those observed when the drug was administered to dogs (28) and to patients at antianginal doses. The 500-or 1,000-mg oral twice a day dose is associated with little change in hemodynamics (heart rate or blood pressure) in patients (2, 16, 18) . In fact, ranolazine is often used in patients with persistent angina who are already taking ␤-blockers, calcium channel blockers, or nitrates and in whom the blood pressure and heart rate have already been lowered to normal levels. In protocol 1, in which coronary occlusion was induced 16 min after ranolazine administration, we cannot rule out that the lower double product might have played some role in the observed anti-arrhythmic effect. The anti-arrhythmic effect of ranolazine in protocol 2 was unlikely due to hemodynamic changes because both heart rate and blood pressure returned to control levels before induction of ischemia (Fig. 5) .
Potential mechanism of action. The mechanism of the antiarrhythmic effect of ranolazine was not the subject of this study. The anti-arrhythmic effects of ranolazine have previously been demonstrated in in vitro models (isolated hearts and myocytes), and much evidence indicates that the principal electrophysiological effect of ranolazine that is likely to contribute to the anti-arrhythmic effects observed in the present study is an inhibition of the late sodium current (I Na ). Late I Na refers to Na ϩ influx through membrane voltage-gated Na ϩ channels after the first few milliseconds of the action potential. Late I Na is enhanced because of inherited or acquired Na ϩ channelopathies that alter channel inactivation and closing (27) . Ranolazine selectively inhibits late I Na (IC 50 ϳ6 M) at therapeutic concentrations (2-8 M), but at much higher concentrations (Ͼ15 M) ranolazine also inhibits delayed rectifying potassium current (I Kr ) (IC 50 ϭ 12-14 M) and may inhibit peak I Na in a rate-dependent manner (1, 8, 11) . Although at higher doses the contribution of other effects cannot be ruled out, the anti-arrhythmic effect observed at the lower dose in this study clearly points to inhibition of late I Na as the mechanism of action of ranolazine. During myocardial ischemia, late I Na contributes to the increase in cytosolic sodium concentration (5, 24) . The increase in sodium leads to an increase in intracellular calcium via activity of the sodium-calcium exchanger (17) . Upon reperfusion of ischemic myocardium, the sudden availability of oxygen in the previously ischemic myocardium may increase the formation of reactive oxygen species which are also known to increase late I Na , thereby worsening sodium and calcium overload (13, 21, 23, 25) . Calcium overload of the cell not only impairs left ventricular relaxation but leads to recurrent spontaneous release of calcium from the sarcoplasmic reticulum, resulting in delayed afterdepolarizations that may lead to ventricular arrhythmias (6) . In in vitro models, ranolazine reduced both afterdepolarizations (arrhythmic triggers) and the transmural and temporal dispersion of repolarization (an arrhythmic substrate) in the myocardium (22, 26) . Thus one potential explanation of the benefit of ranolazine is its late sodium current inhibitor property (1) .
The significance of the findings. The importance of this work is that ranolazine was shown to be a potent anti-arrhythmic agent in the setting of ischemia and ischemia-reperfusion. Currently, there are few anti-arrhythmic therapies available for the treatment of ventricular arrhythmias in the setting of ischemic heart disease. The effect of ranolazine to reduce reperfusion-induced arrhythmias was at least as great as those of pre-and postconditioning in the same experimental model (7, 12) . The observations made in the present study suggest that ranolazine may have therapeutic potential as an anti-arrhythmic agent in the setting of ischemic heart disease. Although our study more closely simulates the early phase of S-T segment elevation MI, recent data from the MERLIN-TIMI 36 outcomes trial (14, 20) support the concept that ranolazine may have anti-arrhythmic properties in patients with non-S-T segment elevation MI. Although ranolazine did not reduce cardiac death in this trial, it did significantly reduce the incidences of nonsustained VTs, supraventricular tachycardias, new-onset atrial fibrillation, and bradyarrhythmias, as determined by analysis of 7-day continuous Holter records from 6,351 patients in the week following randomization (20) . Although therapeutic doses of ranolazine can prolong the QTc interval by ϳ2-6 ms, the drug did not demonstrate a proarrhythmic effect in highrisk patients and did not cause torsade de pointes. The difference between ranolazine and other class I agents is the selectivity of the former for inhibition of late vs. peak sodium current (19) . Reduction of the peak sodium current would itself promote arrhythmias by slowing conduction and enabling reentry, whereas inhibition of late sodium current would be expected to eliminate the occurrence of early and delayed afterdepolarizations (5, 27) . There was no evidence of any proarrhythmic effect in either our study or in the MERLIN Study.
Limitations. One of the limitations of the study is that male rats were used in protocol 1 and female rats were used in protocol 2. The studies were not designed to determine whether the effect of ranolazine is gender dependent. Ranolazine was equally protective in males and females against ischemia-and reperfusion-induced arrhythmias. Other limitations of the study include the issue that the action potential of the rat is not the same as in humans and the relatively acute nature of these studies. However, this model, which is inexpensive and cost effective, may be a useful initial screening tool for potential anti-arrhythmic agents.
In conclusion, there is a lack of anti-arrhythmic therapies available for the treatment of ventricular arrhythmias in the setting of ischemic heart disease. In two independently performed experimental studies, ranolazine was shown to be a powerful anti-arrhythmic agent that reduced ventricular arrhythmias. Further studies exploring the mechanism of the anti-arrhythmic effects of ranolazine are warranted.
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This study was funded by CV Therapeutics. Values are means Ϯ SE from n ϭ 10 in each group. **P Ͻ 0.01 and *P Ͻ 0.05 vs. control using repeated-measures ANOVA. Fig. 7 . Plasma concentrations (M) of ranolazine given as an iv bolus followed by an infusion at 3 doses [low dose (2 mg/kg followed by 4.8 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 ), middle dose (4 mg/kg followed by 7.2 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 ), and high dose (10 mg/kg followed by 9.6 mg ⅐ kg Ϫ1 ⅐ h
Ϫ1
)] in anesthetized rats in protocol 2. Values presented are means Ϯ SD from 4 animals.
